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Abstract
Background: Most mass spectrometry (MS) based proteomic studies depend on searching acquired tandem mass
(MS/MS) spectra against databases of known protein sequences. In these experiments, however, a large number of
high quality spectra remain unassigned. These spectra may correspond to novel peptides not present in the
database, especially those corresponding to novel alternative splice (AS) forms. Recently, fast and comprehensive
profiling of mammalian genomes using deep sequencing (i.e. RNA-Seq) has become possible. MS-based
proteomics can potentially be used as an aid for protein-level validation of novel AS events observed in RNA-Seq
data.
Results: In this work, we have used publicly available mouse tissue proteomic and RNA-Seq datasets and have
examined the feasibility of using MS data for the identification of novel AS forms by searching MS/MS spectra
against translated mRNA sequences derived from RNA-Seq data. A significant correlation between the likelihood of
identifying a peptide from MS/MS data and the number of reads in RNA-Seq data for the same gene was
observed. Based on in silico experiments, it was also observed that only a fraction of novel AS forms identified from
RNA-Seq had the corresponding junction peptide compatible with MS/MS sequencing. The number of novel
peptides that were actually identified from MS/MS spectra was substantially lower than the number expected
based on in silico analysis.
Conclusions: The ability to confirm novel AS forms from MS/MS data in the dataset analyzed was found to be
quite limited. This can be explained in part by low abundance of many novel transcripts, with the abundance of
their corresponding protein products falling below the limit of detection by MS.
Background
Mass spectrometry-based shotgun proteomics has
become the method of choice for the identification and
quantification of proteins from complex biological
samples such as cell lines and tissues [1,2]. In a typical
proteomics experiment, proteins of interest are digested
into peptides using a proteolytic enzyme such as trypsin.
Resulting peptide mixtures are separated by single or
multi-dimensional chromatography coupled online to a
tandem mass spectrometer used to sequence the pep-
tides. The acquired MS/MS spectra are then searched
against protein sequence databases such as RefSeq or
International Protein Index (IPI) database using tools
such as SEQUEST or X! Tandem to identify peptide
sequences (reviewed in [2]). The list of identified pep-
tides is then used to infer the identities of the protein
present in the sample [3].
Recent developments in MS, peptide and protein
separation chemistry, and computational methods for
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feasible [4-6]. However, it has been observed that a sig-
nificant number of high quality spectra in a typical data-
set remain unassigned when searched against existing
protein sequence databases [7,8]. Possible reasons for
this include post-translational modification, either biolo-
gical or chemical, as well as the presence of novel pep-
tides corresponding to protein isoforms not included in
the searched protein database [7-9]. At present, major
protein databases typically used for MS analysis are
incomplete with respect to AS variants predicted from
genomic data in order to keep minimum redundancy
[10]. Moreover, many of these protein isoforms are still
not well annotated [9,11,12]. Translated EST (Expressed
Sequence Tag) databases has been used for MS/MS
search [9,13,14] to identify peptides supporting novel AS
forms, or for verification of peptides identified by the 6-
frame search that could not be aligned perfectly to
known coding regions [15]. However, EST sequences
are redundant [16] and contain many errors originated
from cDNA clones [9,17,18]. Construction of the trans-
lated mRNA sequences based on all hypothetical AS
forms in the genome [19,20] has also been attempted
with some success previously.
Recently, next generation sequencing technique based
on high throughput deep sequencing of complementary
DNAs (RNA-Seq) has emerged as a powerful method
for fast and comprehensive profiling of mammalian
transcriptomes [18,21,22]. Studies using RNA-Seq have
found evidence for many novel exons, and it was also
shown that there were more AS forms than previously
expected [12]. By creating translated mRNA sequences
from RNA-Seq data, MS-based proteomic data can be
used to identify the protein products of these novel
e x o n sa n dA Sf o r m s[ 2 3 ] ,t h u sp r o v i d i n gp r o t e i n - l e v e l
validation for RNA-Seq derived gene models. However,
it remains unclear how many of these novel AS forms
c o u l db ei d e n t i f i e df r o mM S/MS spectra in practice. A
far more fundamental question is how many of these
novel splice forms are actually translated into functional
protein products [24,25]. In this study, we perform a
preliminary analysis using publicly available mouse tis-
sue RNA-Seq data and MS/MS data generated on
mouse mitochondrial proteome in same tissues, with a
focus on the MS-based validation of novel AS forms.
Methods
Construction of translated mRNA sequence database
The first step for novel peptide identification is the gen-
eration of the protein sequence database from mRNA
transcripts predicted by RNA-Seq. Novel mRNA
sequences for novel AS forms are extracted by RNA-Seq
followed by alignment of short reads with known gene
models. Specifically, based on splice reads (junction
reads) from RNA-Seq, novel mRNA sequences corre-
sponding to AS are generated by connecting exons for
which splicing events between them are identified. The
quality of mRNA sequences is then analyzed by statisti-
cal analysis [12], and only high quality mRNA sequences
are used. Translated mRNA sequence database is gener-
ated by translation of all open reading frames (ORFs)
for these novel transcripts by 6-frame translation. To
make translated mRNA sequences suitable for reliable
MS/MS spectral searching, translated ORFs are required
to be at least 30 amino acids long.
Peptide identification via combined database search
For novel peptide identification from translated mRNA
sequences, we have adopted the combined database
search approach: translated mRNA sequences are first
appended to a commonly used protein database (mouse
IPI database in this work). An equal size of reverse
sequences were then generated and appended to the
database as decoys for false discovery rate (FDR) analy-
sis. All MS/MS spectra were searched against this com-
bined database using X!Tandem [26] with k-score [27]
scoring function, and using the following parameters:
parent ion mass tolerance of ±100 ppm, monoisotopic
mass, allowing tryptic peptides only, not more than one
missed trypsin cleavage, and allowing two variable modi-
fications: oxidation and N-terminal acetylation. The
search results were then analyzed by PeptideProphet [3].
Spectra assigned to peptides with probability of 0.9 or
greater (corresponding to an estimated FDR of less than
0.02) were considered assigned. Peptide identifications
were additionally filtered to keep only those based on
high quality MS/MS spectra (quality score above 1
according to QualScore [15]). Among these peptides,
t h o s et h a tw e r ep r e s e n ti nt h et r a n s l a t e dm R N A
sequence database only (and not in the mouse IPI or
mouse subset of NCBI nr database) were considered as
candidate novel peptides. The overall search scheme is
illustrated in Figure 1
Results
Experimental datasets
MS/MS data were taken from a recently published study
on mouse mitochondrial proteome (MitoCarta dataset)
[28], in which in total 1098 mitochondrial genes/pro-
teins (NCBI Entrez genes [29]) were identified from
multiple tissues. Mass spectra were generated using an
LTQ-Orbitrap mass spectrometer. MS/MS data from
three tissues, brainstem (282,360 spectra), liver (256,355
spectra) and skeletal muscle (215,668 spectra) were used
in this study. Gene expression values were directly
downloaded from http://woldlab.caltech.edu/rnaseq/.
Essentially, these values were estimated from RNA-Seq
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mapped reads). for these three tissues were obtained
from Mortazavi et al. [18], which provided comprehen-
sive information about novel exons and AS forms in the
mouse genome. The mouse genome data mm9 is based
on UCSC genome browser [30], obtained from the Build
37 assembly by NCBI and the Mouse Genome Sequen-
cing Consortium, plus gene models annotated by UCSC
and collaborators worldwide. To generate the translated
mRNA sequence database, genome sequences that were
identified by short reads as splice junctions (covered by
at least one unique short reads) and were not in known
gene models in mm9 were translated into protein
sequences by 6 open reading frame translation. In doing
so, 25 amino acids were taken from the two compatible
exons to create junction amino acid sequences, and
shorter junctions were filtered out. There were in total
573,053, 346,895 and 344,537 junctions for AS forms in
the translated mRNA sequence database for brainstem,
liver and skeletal muscle tissues, respectively. The com-
bined database was created by appending the translated
mRNA sequences to the IPI mouse protein sequences
database v3.50 [10] (110,618 entries). Translated EST
sequence database [9] (http://edwardslab.bmcb.george-
town.edu/, version 1.4, accessed 05/15/2009) was also
used to search for novel peptides to compare with the
result of searching translated mRNA sequences.
In silico analysis of the prevalence of AS events that
could be identified by tryptic peptides
Before searching MS/MS spectra against translated
mRNA sequences, we have analyzed the prevalence of
AS from mRNA sequences that could be identified by
tryptic peptides. This analysis was performed in silico in
which the number of tryptic peptides that could straddle
the two exons was computed. This in silico analysis
independent of actual short reads and MS/MS spectra
used, and it is also independent of how translated
mRNA sequences were created.
It was discovered that by mapping junction reads from
RNA-Seq to gene sequences in mm9, most of known
genes contained more than one AS junction (Table 1).
This was true for all mouse genes, but also for the spe-
cific subset of mitochondrial genes that was the subject
of the MS based analysis that produced the dataset of
MS/MS spectra used in this work. However, it was also
observed that less than 6% of all known AS junctions in
mm9 could be identified by tryptic peptides straddling
the intron-exon boundary and having length between 6
and 30 amino acids long - the range most compatible
Figure 1 Overview of the computational strategy.
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tissues) (Table 1). Allowing one missed trypsin cleavage
in peptides (identification of such peptides is less likely)
would less than double this proportion. To further
investigate this, the AS junctions were categorized into
known (translated sequences corresponding to the junc-
tion regions were present in the IPI [10] or NCBI nr
protein sequence database), and potentially novel events.
It was observed that out of all AS predicted, close to
80% were known AS. The proportion of identifiable
junctions was similar among known and novel AS
forms.
We also determined the number of known splice junc-
tions specifically for all 1098 mitochondrial genes anno-
tated in MitoCarta (table 1). On average, there were ~ 5
junctions per gene. Combined with the estimate of the
number of novel junctions given above (~20%), and the
expected proportion that can be identified by tryptic pep-
tides (~5%), one obtains an estimate of approximately 50
novel peptides from mitochondrial proteins that one may
expect to identify from translated mRNA sequences
based on RNA-Seq data. Since the number of mitochon-
drial proteins identified in each individual tissue (brain-
stem, liver or skeletal muscle tissues used in this work)
was actually less than the MitoCarta compendium
(700 on average for each tissue), the expected number
is reduced to ~ 35 peptides. Counting co-purifying non-
mitochondrial proteins also identified in this dataset
brings the expected number of novel peptides back to ~
50 (~80 allowing one missed cleavage). For known AS
forms, the same estimation procedure predicts ~200 pep-
tides (~300 allowing one missed cleavage).
Results of searching MS/MS spectra against the combined
sequence database
For each of the three tissues, the combined database was
created by appending the unique translated mRNA
sequences to the IPI mouse protein sequences database
v3.50 [10] (see Methods). All MS/MS spectra were
searched against this combined database by X!Tandem
[26] followed by PeptideProphet analysis [23]. Peptides
identifications with PeptideProphet probability equal or
greater than 0.9 (corresponding to an estimated FDR =
0.02) were considered identified. This led to 54,906,
59,988 and 46,077 spectra to peptide assignments for
brainstem, liver and skeletal muscle tissues, respectively.
Counting peptide sequences supporting known AS junc-
tions only, there were 494, 301, and 282 identifications
for brainstem, liver, and skeletal muscle tissues, respec-
tively. Note that these numbers are close to the
expected numbers for known AS forms obtained using
in silico estimates described above.
Because the rate of false positives among the candi-
date novel peptides is significantly higher (0.38) than
that among known peptides, we applied a more strin-
gent filtering threshold to achieve an FDR of 0.02 speci-
fically for the subset of novel peptides. In addition, to
further eliminate false positive identifications due to
sequence homology [15], candidate novel peptides were
searched against mouse subset of NCBI nr protein data-
base by BLAST [31], and all peptides with less than
3 mismatches compared to known sequences were
removed from subsequent analysis. Applying these strin-
gent filtering steps, which we believe were warranted,
resulted in the identification of only 2~3 peptide per tis-
sue. These numbers of identified peptides supporting
novel AS junctions is clearly smaller than what is
expected based on the in silico analysis (50-80 peptides).
Furthermore, most of the novel peptides that were iden-
tified from RNA-Seq data could also be identified by
searching against existing translated EST sequence
databases.
Effect of mRNA abundance and the likelihood
of MS-based peptide identification
To gain a better understanding of why such a small num-
ber of novel peptides were identified from MS/MS spec-
tra, we investigated the effect of mRNA abundance on
the likelihood of protein identification. Based on all genes
in the brainstem tissue dataset for which comparison
could be made, we have used RNA-Seq based method
(RPKM) [18] to measure gene expression levels. We then
calculated what fraction of genes in a particular range of
RPKM values that could be identified from MS/MS data.
Table 1 Average number of distinct junctions (AS) per gene for three different tissues in mouse, and average number
of distinct junctions per gene in three different tissues that could be identified by tryptic peptides
Tissue Ave. unique
junctions per gene
(All)
Ave. unique junctions identifiable
by tryptic peptides per gene (All)
Ave. unique junctions
per gene (Mitochondrial)
Ave. unique junctions identifiable by
tryptic peptides per gene (Mitochondrial)
Brainstem 4.00 0.27 5.30 0.29 (0.45)
Liver 2.44 0.16 4.91 0.27 (0.42)
Skeletal
Muscle
2.42 0.16 4.57 0.24 (0.39)
Column 2 and column 3 were based on all junction reads identified by RNA-Seq for all NCBI Entrez genes. Column 4 and column 5 were based on junction reads
by RNA-Seq for 1098 mitochondrial genes. Numbers in brackets were based on tryptic peptides allowing one missed cleavage.
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expression (RPKM value), the more likely the corre-
sponding proteins were identified from MS/MS data. The
proportion of identified proteins dropped quickly with
decreasing RPKM values.
A correlative analysis of RPKM values and protein
abundances extracted from MS data using label-free
quantification based on spectral counts [32,33] indicated
a certain degree of correlation between mRNA and pro-
tein abundance levels (r=0.53) for mitochondrial genes/
proteins in this dataset (N., Kang et al., in preparation).
Thus, the trend shown in Figure 2 (b) reflects, indirectly
via correlation between gene and protein abundances,
the dynamic range limitation of MS-based proteomics.
In other words, proteins present in the cell at lower
abundance are being increasingly underrepresented in
the lists of identified proteins. This suggests that the
identification of peptides for novel exons or AS forms
requires that the corresponding genes have a relatively
high gene expression levels. The average lower abun-
dance (short read count) of novel AS forms identified in
RNA-Seq, as compared to that for known AS forms,
may be one factor contribution to lower than expected
rate of identification of novel junction peptides from
MS/MS data.
Efficiency of novel peptide identification process
All of the experiments were performed on a Linux ser-
ver with 2.2 GHz CPU and 4.0GB RAM. The novel pep-
tide identification process based on combined database
was very efficient: the overall process of novel peptide
identification from mass spectra for mitochondrial genes
in brain tissue was within 3 hours, and most of the time
was consumed by combined database search. Candidate
novel peptide filtration based on searching known
databases was fast due to the small number of candidate
novel peptides.
Conclusions
Deep sequencing by RNA-Seq allows comprehensive
analysis of alternative splicing and identifies a large
number of novel alternative splice isoforms. In this
study, we have tried to use MS-based proteomic data
for protein-level validation of these novel AS events
using a publicly available dataset on mouse mitochon-
drial proteome. We were particularly interested in
understanding what fraction of novel peptides could be
identified from translated mRNA sequences, and
what factors affect the detectability of novel AS from
MS/MS data. It is one of the first works in the field of
connecting RNA-Seq data and MS/MS based proteo-
mics data.
We observed that only a small proportion of novel
RNA-Seq derived AS events could be validated by MS/
MS spectra. Additionally, most of the novel peptides
that we were able to identify could also be identified by
searching against existing translated EST sequence data-
bases. The smaller number of identified novel peptides
than expected based on in silico analysis can in part be
explained by lower abundance of the corresponding pro-
tein forms (below the range of detection of the mass
spectrometer). It has also being suggested that only a
small fraction of the alternative splice forms observed in
the transcriptome data are functional and contribute to
the diversity of the proteome [24,25]. This fundamental
question should be addressed in future work.
This work has actually pointed out that current
attempt to validate genome annotation based on proteo-
mic data still has a lot of obstacles, both in data extrac-
tion and computational met h o d .H o w e v e r ,c u r r e n t
method could still confidently identify some novel AS
events from the combination of RNA-Seq data and pro-
teomics data. Therefore, this work represents an effort
of trying to find proteomic validation for genome anno-
tation, which is very promising. Although the data used
and approaches taken in this study are primary, and the
results are not very promising, it may lead into the
direction of addressing similar goals (e.g., more accurate
gene annotation with the aid of proteomic data) using
more diverse sets of matching RNA-Seq and proteomic
data in the future.
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